THYROID EYE DISEASE
Clinical trials for THYROID EYE DISEASE explained in plain language.
Never miss a new study
Get alerted when new THYROID EYE DISEASE trials appear
Sign up with your email to follow new studies for THYROID EYE DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to ease bulging eyes in thyroid disease patients
Disease control OngoingThis study tests a medicine called Lu AG22515 in 20 adults with moderate-to-severe thyroid eye disease, an autoimmune condition that causes eye swelling and bulging. The main goal is to see if the treatment reduces bulging eyes over 24 weeks. Researchers will also check how the d…
Matched conditions: THYROID EYE DISEASE
Phase: PHASE1 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated May 17, 2026 07:00 UTC
-
New hope for thyroid eye disease: phase 3 drug trial shows promise
Disease control OngoingThis study tests an investigational drug called VRDN-003 in 132 people with active thyroid eye disease, a condition that causes eye bulging, redness, and discomfort. The goal is to see if the drug can reduce eye bulging by at least 2 millimeters compared to a placebo. Participant…
Matched conditions: THYROID EYE DISEASE
Phase: PHASE3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug could ease bulging eyes in thyroid disease
Disease control OngoingThis study tests a drug called satralizumab for people with moderate-to-severe thyroid eye disease, a condition that causes eye bulging, pain, and double vision. About 131 adults will receive either the drug or a placebo to see if it reduces eye bulging by at least 2 millimeters …
Matched conditions: THYROID EYE DISEASE
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Promising drug may reduce bulging eyes in thyroid disease
Disease control OngoingThis study tests a drug called satralizumab in 127 people with moderate-to-severe thyroid eye disease, a condition that causes eye bulging, double vision, and pain. The main goal is to see if the drug reduces eye bulging by at least 2 millimeters after 24 weeks. Participants rece…
Matched conditions: THYROID EYE DISEASE
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for chronic thyroid eye disease: phase 3 trial launched
Disease control OngoingThis study tests an investigational drug called VRDN-003 in 195 people with chronic thyroid eye disease, a condition that causes eye bulging and discomfort. The goal is to see if the drug can reduce eye bulging by at least 2 millimeters compared to a placebo. Participants receive…
Matched conditions: THYROID EYE DISEASE
Phase: PHASE3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New shot for bulging eyes moves to final testing phase
Disease control OngoingThis study tests an investigational drug called VRDN-003 for people with thyroid eye disease (TED). The main goal is to see if the drug is safe and how the body processes it. About 87 adults with TED will receive the drug as a shot under the skin. This is a Phase 3 trial, meaning…
Matched conditions: THYROID EYE DISEASE
Phase: PHASE3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
Promising injection could ease bulging eyes in thyroid disease
Disease control OngoingThis study tests an injected drug called teprotumumab in people with moderate-to-severe active thyroid eye disease, a condition that causes eye bulging and discomfort. About 89 adults will receive either the drug or a placebo to see if it reduces eye bulging by at least 2 mm with…
Matched conditions: THYROID EYE DISEASE
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated May 08, 2026 12:01 UTC
-
New injection could ease bulging eyes from thyroid disease
Disease control OngoingThis study tests a new drug called TOUR006 for people with active thyroid eye disease, which causes eye bulging and inflammation. About 79 participants will receive either a low dose, high dose, or placebo injection every 8 weeks. The goal is to see if the drug can reduce eye bul…
Matched conditions: THYROID EYE DISEASE
Phase: PHASE2 • Sponsor: Tourmaline Bio, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC